Rapport Therapeutics completed its initial public offering (IPO) in 2024, with its stock price fluctuating between $24.37 and $52.50 over the past year. Recent stock events include the May 7, 2026, report of First Quarter 2026 Financials and a business update, highlighting sustained seizure reduction data for RAP-219 in focal onset seizures, an accelerated timeline for RAP-219 Phase 2 trial topline results in bipolar mania (now expected in Q4 2026), and the on-track initiation of the RAP-219 Phase 3 program in focal onset seizures for Q2 2026. The company announced participation in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference on May 20, 2026. News emerged on June 12, 2026, about rapportrx.com launching a seizure drug solo. On August 5, 2026, Rapport Therapeutics reported its Second Quarter 2026 Financials and a business update, reporting ($1.19) earnings per share, missing analysts' consensus estimates of ($1.12). Wall Street Zen downgraded Rapport Therapeutics from a 'hold' to a 'sell' rating on August 8, 2026. CEO Abraham Ceesay sold 28,958 shares of the firm's stock on August 11, 2026. HC Wainwright increased their target price on Rapport Therapeutics from $40.00 to $66.00 and gave the stock a 'buy' rating on August 12, 2026. Rapport Therapeutics hosted a virtual KOL event on the unmet need in bipolar mania and the RAP-219 clinical program on August 24, 2026. The company announced participation in upcoming investor conferences on September 2, 2026. UBS Group set an $80.00 price objective, and Citigroup reaffirmed a 'market outperform' rating on September 23, 2026. CEO Abraham Ceesay reported direct sales of 3,375 shares and 1,147 shares, respectively, under Rule 10b5-1 trading plans on October 6-7, 2026. Guggenheim upgraded Rapport Therapeutics to a 'strong-buy' rating on October 7, 2026. The stock closed at $29.85 on October 8, 2026.
